The business may not be as strong as its performance this year suggests.

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Cantai launched in 2023 with a $3 million seed round. The company has raised $6.55 million to date at an undisclosed valuation, according to PitchBook. It develops drug candidates with special ...

State officials on Monday have announced renovation plans at SUNY Upstate Medical Center’s CNY Biotech Accelerator as well as nearly $3 million in funding to help advance the ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

FAR Biotech, a computational drug discovery company, has officially relocated to Wisconsin. The move marks a significant ...

Hands-on biotech training delivers credentials, research projects, and real lab access for San Antonio students—fueling ...